Mr. Botelho has more than 30 years of experience in biopharmaceutical product development. He is a Managing Partner at InVenture Partners LLC. Prior to this position, he was the President, Americas for EUSA Pharma where he was responsible for establishing US, Canadian and South American organizations. He was integrally involved with development of the US business plan, business development efforts for product acquisition, and the assessment of M&A candidates which culminated in acquisition of Cytogen. Prior to that, he was Head of Commercial Development at Celator Pharmaceuticals, a biotechnology company working to develop improved combination chemotherapies for different forms of cancer. He was a founder and Chief Business Officer of Zeneus Pharma, a European hospital specialty pharmaceutical company acquired by Cephalon in December 2005. Prior to that, Mr. Botelho held a range of senior positions at Merck & Co., Inc., including commercial operations, corporate and business development and new product planning and was Vice President, International Sales & Operations for the Merck Vaccine Division, a position he held from 1998 until 2002. In this capacity he led all commercial activities for Merck's vaccine business outside of the United States.
Alejandro has 10 years experience in business development finance, marketing, and fundraising in the life sciences. Previously Alejandro was the VP of Business Development at PainQx handling strategy and fundraising efforts.
Previously Alejandro was Co-Founder & VP of Business Development at Life Science Nation (LSN), an online platform that helps entrepreneurs connect with investors that fit their investment needs. During Alejandro’s tenure at LSN, the business grew from 1 to 22 employees, opened of a broker-dealer (Boston Innovation Capital), created a quarterly conference (Redefining Early Stage Investments), and the launched the LSN Company and Investor Platform.
Previous to LSN Alejandro was Business Development Executive at Abpro a CRO specializing in the development of recombinant proteins, monoclonal antibodies, and the associated assay development. Alejandro joined Abpro as a financial analyst responsible for securing funding. He was then promoted to a role in Business Development. In this role, Alejandro formed discovery and development-stage collaborations with the industry’s largest pharmaceutical companies such as Novartis, Astellas, Boehringer Ingelheim, and Abbott (Now Abbvie).